MAPK14 and prostate carcinoma: Through systematic analysis of nine high‐risk contaminants, we identified pan‐cancer targets and key pathway modules, with subsequent validation of hub genes (JUN, CDC42, MAPK14) in breast, colon, and prostate cancers using TCGA datasets.